A method for making the compound is set forth utilizing the starting material

Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent optionally with another active agent e.g. anti-HIV agents and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets and methods of treating HIV.

In the present invention there are described soluble CTLA4 fusion molecules containing extracellular domain of the CTLA4 molecule and their use optionally in combination with a second agent being selected from the group consisting of corticosteroids nonsteroidal anti-inflammatory agents cyclosporine prednisone azathioprine methotrexate TNF-alpha blockers or antagonists hydroxychloroquine sulphasalazine gold salts anakinra cyclophosphamide and leflunomide and their use as well as pharmaceutical c...

This invention provides for prodrug Compounds I pharmaceutical compositions thereof and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N R1 does not exist; W is C or N with the proviso that when W is N R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are in...

The invention relates to a process for production of a compound of formula B-OCFCFH comprising reducing a mixture containing a compound of formula B-OCFCFH and a compound of formula B-OCFCFBr with zinc dust under acidic conditions.

The disclosure provides compounds of formula I including their salts as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic alpha7 receptor and may be useful for the treatment of various disorders of the central nervous system especially affective and neurodegenerative disorders.

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such...

In the present invention there are described compounds having drug and bio-affecting properties their pharmaceutical compositions and method of their use. In particular the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity whether used alone or in combination with other antiviral medicaments antiinfective medicaments and immunomodulators or HIV entry inhibitors. More particularly the present invention relates to the treatment...

The present invention relates to cyclic compounds of formula II and salts thereof to methods of using such compounds in treating protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and to pharmaceutical compositions containing such compounds.